Ascendis Pharmac (ASND.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow

Quote List Quote List

Event Tracking

Dec12

Stifel Nicolaus Raises Ascendis Pharma Target Price

19:28

Dec9

Ascendis Pharma A/S's stock price falls short of earnings expectations

18:38

Nov30

Ascendis Pharma's FDA Review Extended with High Stock Returns

22:09

Nov25

Ascendis Pharma's TransCon CNP Review Period Extended by Three Months

23:16

Nov19

JPMorgan, Bank of America and Wells Fargo all assign Ascendis Pharma A/S stock a 'Buy' or 'Outperform' rating

16:59

Nov17

Ascendis Pharmaceuticals Announces Positive Phase 3 Clinical Trial Results for TransCon CNP

21:01

Schedules & Filings

Schedules

Filings

Nov12

Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 250.54 M, Net Income -71.52 M, EPS -1.1772

Aug7

Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 185 M, Net Income -45.48 M, EPS -0.7523

May1

Earning Release(EST)

FY2025 Q1 Earning Release (USD) Revenue 109.28 M, Net Income -102.43 M, EPS -1.7066

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change